Fosun Pharma Receives Regulatory Inquiry Letter from SSE Over Planned Controlling Stake Acquisition of Green Valley Pharmaceutical
December 16, 2025
Source: drugdu
31
On December 16, the Shanghai Stock Exchange (SSE) issued a regulatory inquiry letter to Fosun Pharma regarding its external investment in Green Valley Pharmaceutical, addressing matters related to the listed company.
On December 15, Fosun Pharma announced that its controlling subsidiary, Fosun Pharma Industrial, had entered into a relevant investment agreement with Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. (“Green Valley Pharmaceutical”) and its existing shareholders. The agreement involves an investment of approximately RMB 1.412 billion to acquire a controlling stake in Green Valley Pharmaceutical. Upon completion of the acquisition, Green Valley Pharmaceutical will become a controlling subsidiary of Fosun Pharma, and its core drug, Sodium Oligomannate Capsules, will be integrated into Fosun Pharma’s innovative drug pipeline. The drug is primarily indicated for the treatment of mild to moderate Alzheimer's disease.
Reference: https://finance.eastmoney.com/a/202512163592385827.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- FDA Approves Lerochol for Adults with Elevated LDL Cholesterol December 16, 2025
- How to Head Off Tendon Trouble December 16, 2025
- Ascletis Pharma’s ASC50 Phase I clinical trial in the United States yielded positive topline results December 16, 2025
- Hualan Biological’s application for clinical trial of pembrolizumab injection has been accepted December 16, 2025
- Another Phase 3 clinical trial failed. December 16, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
